These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Nadroparin calcium. A review of its pharmacology and clinical applications in the prevention and treatment of thromboembolic disorders. Barradell LB; Buckley MM Drugs; 1992 Nov; 44(5):858-88. PubMed ID: 1280570 [TBL] [Abstract][Full Text] [Related]
5. [Calcium nadroparin in the prevention of thromboembolic disease in elderly subjects. Study of tolerance]. Forette B; Wolmark Y Presse Med; 1995 Mar; 24(12):567-71. PubMed ID: 7770402 [TBL] [Abstract][Full Text] [Related]
6. [Therapeutic management of superficial venous thrombosis with calcium nadroparin. Dosage testing and comparison with a non-steroidal anti-inflammatory agent]. Titon JP; Auger D; Grange P; Hecquet JP; Remond A; Ulliac P; Vaissié JJ Ann Cardiol Angeiol (Paris); 1994 Mar; 43(3):160-6. PubMed ID: 8024227 [TBL] [Abstract][Full Text] [Related]
7. An observational study on the effects of nadroparin-based and citrate-based continuous venovenous hemofiltration on calcium metabolism. van der Voort PH; Postma SR; Kingma WP; Boerma EC; de Heide LJ; Bakker AJ Blood Purif; 2007; 25(3):267-73. PubMed ID: 17446700 [TBL] [Abstract][Full Text] [Related]
8. Calcifying panniculitis following subcutaneous injections of nadroparin-calcium in a patient with osteomalacia. Campanelli A; Kaya G; Masouyé I; Borradori L Br J Dermatol; 2005 Sep; 153(3):657-60. PubMed ID: 16120161 [TBL] [Abstract][Full Text] [Related]
9. Comparison of a low-molecular-weight heparin (nadroparin calcium) and unfractionated heparin as adjunct to coronary thrombolysis with alteplase and aspirin in dogs. Jun L; Arnout J; Vanhove P; Dol F; Lormeau JC; Herbert JM; Collen D; Van de Werf F Coron Artery Dis; 1995 Mar; 6(3):257-63. PubMed ID: 7788040 [TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of weight-adapted nadroparin calcium vs. heparin sodium in prevention of clinically evident thromboembolic complications in 1,190 general surgical patients. Egger B; Schmid SW; Naef M; Wildi S; Büchler MW Dig Surg; 2000; 17(6):602-609. PubMed ID: 11155006 [TBL] [Abstract][Full Text] [Related]
11. Iatrogenic calcinosis cutis following nadroparin injection. Giorgini S; Martinelli C; Massi D; Lumini A; Mannucci M; Giglioli L Int J Dermatol; 2005 Oct; 44(10):855-7. PubMed ID: 16207189 [TBL] [Abstract][Full Text] [Related]
12. Nadroparin-induced Calcinosis cutis in renal transplant recipients. van Haren FM; Ruiter DJ; Hilbrands LB Nephron; 2001 Mar; 87(3):279-82. PubMed ID: 11287765 [TBL] [Abstract][Full Text] [Related]
13. Economic evaluation of the use of nadroparin calcium in the prophylaxis of deep vein thrombosis and pulmonary embolism in surgical patients in Italy. Lloyd A; Aitken JA; Hoffmeyer UK; Kelso EJ; Wakerly EC; Barber ND Pharmacoeconomics; 1997 Oct; 12(4):475-85. PubMed ID: 10174313 [TBL] [Abstract][Full Text] [Related]
14. Nadroparin carries a potentially high risk of inducing cutaneous delayed-type hypersensitivity responses. Schindewolf M; Recke A; Zillikens D; Lindhoff-Last E; Ludwig RJ Contact Dermatitis; 2017 Jul; 77(1):35-41. PubMed ID: 28294347 [TBL] [Abstract][Full Text] [Related]
15. Nadroparin calcium. A review of its pharmacology and clinical use in the prevention and treatment of thromboembolic disorders. Davis R; Faulds D Drugs Aging; 1997 Apr; 10(4):299-322. PubMed ID: 9108990 [TBL] [Abstract][Full Text] [Related]
16. Effects of nadroparin on bone histomorphometric parameters in rats. Folwarczna J; Janiec W; Barej M; Cegieła U; Pytlik M; Kaczmarczyk-Sedlak I Pol J Pharmacol; 2004; 56(3):337-43. PubMed ID: 15215564 [TBL] [Abstract][Full Text] [Related]